Cancer patients who receive neoadjuvant therapy followed by mastectomy may not need radiation

September 25, 2008

BOSTON - Early-stage breast cancer patients who exhibit limited lymph node involvement may not require post-surgery radiation therapy (RT) when they receive neoadjuvant chemotherapy before a mastectomy, according to researchers from The University of Texas M. D. Anderson Cancer Center.

The findings were reported today at the 50th Annual meeting of the American Society for Therapeutic Radiology and Oncology.

"Radiation after surgery has been shown to benefit the survival of patients who have more advanced tumors," said Tse-Kuan Yu, M.D., Ph.D., assistant professor in M. D. Anderson's Department of Radiation Oncology. "However, administering neoadjuvant chemotherapy prior to surgery has changed how radiation oncologists need to approach treating patients with stage one and two breast cancers."

The retrospective study led by Yu reviewed the cases of 427 women who underwent neoadjuvant chemotherapy and mastectomy from 1985-2004 to observe the value of treating early-stage breast cancer with RT. Of the 427 women, radiation was administered to 253 due to more aggressive tumor features. Those who received radiation more commonly had four or more pathologically involved lymph nodes or lymphovascular invasion.

Specifically focusing on those who did not receive RT, researchers looked at whether each patient's breast cancer relapsed over the course of five years to determine if radiation contributed to preventing its return. Of the group of patients who were not treated with radiation, 20 percent of those with four or more pathologically involved lymph nodes after pre-surgery chemotherapy relapsed compared to 4.2 percent of those with one to three involved lymph nodes.

Interestingly, researchers noted that patients with zero involved lymph nodes after receiving chemotherapy prior to surgery exhibited a zero percent recurrence rate.

"Our findings indicate neoadjuvant chemotherapy controlled the cancer and radiation would have been unnecessary for patients with early-stage breast cancer and negative lymph nodes after neoadjuvant chemotherapy," said Thomas Buchholz, M.D., Chair, Department of Radiation Oncology at M. D. Anderson, the study's senior author. "Though additional research is warranted, we can begin to surmise that patients can be spared from radiation therapy if they have been treated with neoadjuvant chemotherapy and have less than three involved lymph nodes."

By analyzing initial tumor characteristics in each patient, researchers can begin to classify which patients require post-mastectomy radiation to prevent recurrence. To expand on these findings, researchers at M. D. Anderson are planning future prospective clinical trials that would confirm whether radiation can be avoided in selected patients with early-stage breast cancer who are treated with neoadjuvant chemotherapy.

University of Texas M. D. Anderson Cancer Center

---

---

	Neoadjuvant Chemotherapy In Invasive Bladder Cancer (DISCONTINUED (Progress in Clinical and Biological Research)) by TED,ED. SPLINTER (Author) This treatise examines the value of neoadjuvant chemotherapy for survival or bladder preservation. Using a multidisciplinary approach, it describes the results of clinical trials involving 35 patients and offers conclusions that can be compared with other studies and may reveal alternative methods to chemotherapy. Specifically covered are criteria for neoadjuvant chemotherapy eligibility, the extent of staging and restaging procedures, uniform definitions for the assessment of response, and the numerous types and extent of locoregional therapy following chemotherapy.
	Neoadjuvant Chemotherapy (Colloque INSERM) by Jacquillat C (Author)
	Proceedings of the 3rd International Congress on Neo-Adjuvant Chemotherapy by Pierre Banzet (Editor), J.F. Holland (Editor), David Khayat (Editor), M. Weil (Editor) This book brings together major papers presented during the 3rd International Congress on Neo-adjuvant Chemotherapy. It offers a panoramic view of the international experience of neo-adjuvant chemotherapy that is intended to help direct the reader towards better and more effective therapeutic strategies. Cancer treatment can be improved by metabolic manipulation (PFL), intensifying the doses, using growth factors and autologous grafts, increasing the concentration at the tumour site by intra-arterial injection (a technique particularly used for gastrointestinal tumours), and combining chemotherapy with biological response modifiers. Neo-adjuvant chemotherapy has been used successfully in the treatment of upper respiratory/gastrointestinal tumours, in breast tumours and lung cancers,...
	21st Century Understanding Cancer Toolkit: Chemotherapy, Management of Side Effects, Trials, Investigational Drugs - Information for Patients, Families, Caregivers about Chemo by Progressive Management Authoritative information, tips, and practical advice from the nation's cancer experts about chemotherapy, providing coverage of all aspects of this vital form of cancer therapy, with particular emphasis on the practical management of side effects. Starting with the basics, and advancing to detailed patient-oriented information, this comprehensive compilation gives empowered patients, families, and caregivers the information they need to understand chemotherapy in all its forms. Conveniently organized contents include: Chemotherapy and You * Managing Chemotherapy Side Effects - Sexual and Fertility Changes in Men * Anemia * Appetite Changes * Bleeding Problems * Constipation * Memory Changes * Mouth and Throat Changes * Nerve Changes * Pain * Sexual and Fertility Changes in Women * Skin...
	Ondansetron and Chemotherapy Induced Emesis: 3rd International Congress on Neo-Adjuvant Chemotherapy by M. Marty (Author), M. Pappo (Editor) During the 3rd International Congress on Neoadjuvant Chemotherapy (Paris 1991) a complete symposium was devoted to chemically induced nausea and vomiting and to the value of Ondansetron. This book comprises original articles dealing with the different topics discussed during this session. It provides fuller information on current practice in anti-emetic treatment during anti-cancerous chemotherapy and sets out the position of a new and important drug, ondansetron, in this pathology. Different international clinical studies made with ondansetron in various types of patients are analysed: specific studies in hematology or in pulmonary disease, evaluation against benzamide-corticoid as a combined reference standard, or...
	Neoadjuvant Chemotherapy: International Congress Proceedings by Claude Jacquillat (Editor)
	Handbook of Cancer Chemotherapy (Lippincott Williams & Wilkins Handbook Series) by Roland T. Skeel (Author), Samir Khleif (Author) Skeel's Handbook of Cancer Chemotherapy combines in one place the most current rationale and specific details necessary to safely administer chemotherapy for most adult cancers. The handbook is a practical, diseased-focused pocket reference that emphasizes the best current medical practice as it relates to the delivery of chemotherapeutic drugs. By focusing on specific plans for treatment, the book is an invaluable resource for the daily care of cancer patients.
	Cancer Chemotherapy and Biotherapy: Principles and Practice (Chabner, Cancer Chemotherapy and Biotherapy) by Bruce A. Chabner (Editor), Dan L. Longo (Editor) Updated to include the newest drugs and those currently in development, Cancer Chemotherapy and Biotherapy, Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents—their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. Chapters emphasize pharmacology and mechanisms of action at the molecular and cellular levels, followed by clinical activity and toxicity, both acute and delayed. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations. This edition's introduction includes...
	Nurse's Chemotherapy Quick Pocket Reference by Debra S. Prescher-Hughes (Author) Nurse's Chemotherapy Quick Pocket Reference is a portable, quick-reference guide that provides quick access to the essentials of chemotherapy dosing administration and is arranged alphabetically by cancer type. This resource covers drug information for over 40 cancer types including bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, leukemia, lung cancer, ovarian cancer, prostate cancer, thyroid cancer, and more, and includes pre-treatment information, chair time, and major side effects for each drug entry. All the chemotherapy drug information you need in the palm of your hand!
	Coping with Chemotherapy: Compassionate Advice and Authoritative Information from a Chemotherapy Survivor by Nancy Bruning (Author) After undergoing chemotherapy herself, author Nancy Bruning decided to write a candid and authoritative book to fill the void of information available for patients facing this procedure. In this completely revised, updated, and thoroughly researched edition, she details every step of the process, providing information even doctors neglect to tell their patients, including possible sexual and emotional side effects and ways to combat them. Coping with Chemotherapy is a must-read for anyone battling cancer.